The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...
GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...
For GSK’s Ramakrishnan, who has served as CDTO since 2021, the biggest challenge was helping her company get a head start in ...
Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...
Blujepa marks the first new oral antibiotic to gain FDA approval for uncomplicated urinary tract infections in nearly 30 ...
After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...
Soon after President Trump won the presidential election in November, GSK brought an unusual claim to federal prosecutors in Manhattan, The Wall Street Journal reports. A senior GSK scientist ...
GSK’s Blujepa receives US FDA nod to treat uncomplicated urinary tract infections in female and paediatric patients 12 years of age and older: Philadelphia Friday, March 28, 202 ...
To test it prospectively, GSK will work with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) ...
London: GSK plc has announced that the Company has received US Food and Drug Administration (FDA) approval for Blujepa ...
With GSK shipping 500 million vaccine doses and up to 1.8 billion packs of medicine last year, the scalability benefits are clear. A challenge not isolated to the pharmaceutical sector is getting ...